Compare Stocks

→ “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVEO AVEO Pharmaceuticals	$15.00	$14.97	$3.06 ▼ $15.00	$521.45M	1	601,442 shs	247,800 shs
CYDY CytoDyn	$0.15	$0.17	$0.13 ▼ $0.42	$147.44M	0.16	1.32 million shs	648,615 shs
ETON Eton Pharmaceuticals	$3.20 -0.3%	$3.93	$2.42 ▼ $5.81	$82.20M	1.17	66,420 shs	9,968 shs
SESN Sesen Bio		$10.50	$0.37 ▼ $12.58	$2.56B	0.83	1.07 million shs	93,330 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVEO AVEO Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CYDY CytoDyn	-1.00%	+0.34%	-11.61%	-15.19%	-48.79%
ETON Eton Pharmaceuticals	-2.13%	+2.23%	-17.27%	-27.70%	-8.55%
SESN Sesen Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	2.1126 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.8	0.0
SESN Sesen Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	3.00	Buy	$10.00	212.50% Upside
SESN Sesen Bio	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVEO AVEO Pharmaceuticals	$42.29M	12.33	N/A	N/A	$1.33 per share	11.28
CYDY CytoDyn	$270K	546.08	N/A	N/A	($0.12) per share	-1.24
ETON Eton Pharmaceuticals	$31.64M	2.60	$0.00 per share	1,026.35	$0.60 per share	5.33
SESN Sesen Bio	$40M	0.00	N/A	3.39	$0.78 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVEO AVEO Pharmaceuticals	-$53.34M	-$0.84	N/A	28.85	N/A	-30.79%	-81.66%	-28.83%	N/A
CYDY CytoDyn	-$79.82M	-$0.05	N/A	∞	N/A	N/A	N/A	-478.47%	N/A
ETON Eton Pharmaceuticals	-$940K	-$0.03	N/A	∞	N/A	-2.96%	-6.21%	-3.17%	5/9/2024 (Estimated)
SESN Sesen Bio	-$19.88M	-$0.10	N/A	N/A	N/A	N/A	6.70%	5.41%	N/A

Latest AVEO, CYDY, SESN, and ETON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/15/2024	Q3 2024	CYDY CytoDyn	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A
3/14/2024	Q4 2023	ETON Eton Pharmaceuticals	-$0.04	-$0.09	-$0.05	-$0.09	$7.70 million	$7.31 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SESN Sesen Bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVEO AVEO Pharmaceuticals	0.94	2.37	2.35
CYDY CytoDyn	N/A	0.08	0.08
ETON Eton Pharmaceuticals	N/A	1.65	1.60
SESN Sesen Bio	N/A	6.10	6.10

Ownership

Institutional Ownership

Company	Institutional Ownership
AVEO AVEO Pharmaceuticals	49.95%
CYDY CytoDyn	5.06%
ETON Eton Pharmaceuticals	27.86%
SESN Sesen Bio	16.45%

Insider Ownership

Company	Insider Ownership
AVEO AVEO Pharmaceuticals	3.29%
CYDY CytoDyn	0.71%
ETON Eton Pharmaceuticals	13.16%
SESN Sesen Bio	3.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AVEO AVEO Pharmaceuticals	114	34.76 million	33.62 million	Optionable
CYDY CytoDyn	12	992.87 million	985.82 million	Not Optionable
ETON Eton Pharmaceuticals	30	25.69 million	22.31 million	Optionable
SESN Sesen Bio	35	203.49 million	196.98 million	Optionable

AVEO, CYDY, SESN, and ETON Headlines

Source	Headline
	Trey Mewes startribune.com - April 10 at 12:53 AM
	Devin Haney: biography, record, fights and more espn.com - December 9 at 5:50 PM
	Tyson Fury: Biography, record, fights and more espn.com - December 2 at 10:49 AM
	Why the Tucker Carlson Biography Sales Are So Pathetic thedailybeast.com - September 13 at 10:23 PM
	Sesen Bio (NASDAQ: SESN) fool.com - August 4 at 6:23 PM
	James McTeigue Biography & Movies tribute.ca - May 10 at 6:46 PM
	After revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen Bio bizjournals.com - March 6 at 7:17 PM
	Sesen Bio wins shareholder approval for Carisma merger msn.com - March 2 at 1:30 PM
	Sesen Bio Stockholders Approve Merger with Carisma Therapeutics finance.yahoo.com - March 2 at 1:30 PM
	Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results finance.yahoo.com - February 28 at 12:42 PM
	SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations benzinga.com - February 24 at 9:19 PM
	Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carisma finance.yahoo.com - February 21 at 10:50 AM
	BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics stockhouse.com - February 17 at 8:59 PM
	Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting businesswire.com - February 16 at 4:47 PM
	Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger finance.yahoo.com - February 16 at 9:10 AM
	Sesen Bio reaches deal with investor group, paving way for Carisma merger endpts.com - February 15 at 2:11 PM
	Latest terms of Sesen Bio and Carisma merger appear to pass muster thepharmaletter.com - February 15 at 2:11 PM
	5 big dividend moves: Group 1 Automotive hikes by 20% \| Pro Recap finance.yahoo.com - February 15 at 9:11 AM
	BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics finance.yahoo.com - February 15 at 9:11 AM
	Sesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor group bizjournals.com - February 14 at 2:01 PM
	Sesen gains 11% on amended terms for merger with Carisma msn.com - February 14 at 9:00 AM
	Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger finance.yahoo.com - February 14 at 9:00 AM
	Sesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years ago finance.yahoo.com - February 6 at 10:17 AM
	Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger finance.yahoo.com - February 2 at 7:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AVEO Pharmaceuticals

NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

CytoDyn

OTCMKTS:CYDY

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Eton Pharmaceuticals

NASDAQ:ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Sesen Bio

NASDAQ:SESN

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial